Search - tctmd.com

Displaying 941 - 960 of 1230

Sort: Relevancy | Date

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Todd Neale

November 09, 2017

News Conference News TCT 2017

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

Ashley Lyles

November 08, 2017

News Conference News TCT 2017

Early Pilot Study Results Show Symptom Improvement With TMVR

Michael O'Riordan

November 07, 2017

News Conference News TCT 2017

MAVERIC: Transcatheter MV Repair Shows Continued Efficacy, Safety at 6 Months

TCT Daily Staff

November 06, 2017

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

Todd Neale

November 02, 2017

News Conference News TCT 2017

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

Yael L. Maxwell

November 02, 2017

News Conference News TCT 2017

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Yael L. Maxwell

November 01, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

Case #1 Introduction: Low-Risk 65-Year-Old Patient With Severe Aortic Stenosis Refuses Surgical TAVR Because They Want TAVR

Presenter: Nick Curzen, Rod H. Stables

October 31, 2017

Presentation TCT 2017

The NOTION 2 Low-risk Trial in Younger Patients

Presenter: Lars Sondergaard

October 30, 2017

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Presenter: Thomas Walther

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

MitraClip For the Low and Intermediate Risk Degenerative MR Patient: Ethics and Outcomes

Presenter: Ted Feldman, Scott Lim, James B. Hermiller Jr.

October 30, 2017

Presentation TCT 2017

Case Presentation: Mitraclip in a Low to Intermediate Surgical Risk Patient With Degenerative MR

Presenter: Ted Feldman, Scott Lim, Michael J. Rinaldi

October 30, 2017

Presentation TCT 2017

Conclusions and Take-home Messages

Presenter: Dariusz Dudek, Martin Hudec

October 30, 2017

Presentation TCT 2017

Germany Presents: Case Conclusion - How I Treated This Case

Presenter: Dariusz Dudek, Martin Hudec, Julia Seeger

October 30, 2017

Presentation TCT 2017

Slovakia Comments: How Would I Treat This Case?

Presenter: Dariusz Dudek, Martin Hudec, Branislav Liska

October 30, 2017

Presentation TCT 2017

Germany Presents: Case Introduction - TAVR in a Low-Risk Patient With Cerebral Embolic Protection

Presenter: Dariusz Dudek, Martin Hudec, Julia Seeger

October 30, 2017

Advertisement

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

Early Pilot Study Results Show Symptom Improvement With TMVR

MAVERIC: Transcatheter MV Repair Shows Continued Efficacy, Safety at 6 Months

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Case #1 Introduction: Low-Risk 65-Year-Old Patient With Severe Aortic Stenosis Refuses Surgical TAVR Because They Want TAVR

The NOTION 2 Low-risk Trial in Younger Patients

The Evolut R Low-risk Trial

The PARTNER 3 Low-risk Trial

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

MitraClip For the Low and Intermediate Risk Degenerative MR Patient: Ethics and Outcomes

Case Presentation: Mitraclip in a Low to Intermediate Surgical Risk Patient With Degenerative MR

Conclusions and Take-home Messages

Germany Presents: Case Conclusion - How I Treated This Case

Slovakia Comments: How Would I Treat This Case?

Germany Presents: Case Introduction - TAVR in a Low-Risk Patient With Cerebral Embolic Protection

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content